30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now
United States Biotechnology & Medical Research

Aktis Oncology Inc (AKTS)

Track

The most recent insider trading activity occurred on January 12, 2026. Significant buying activity was observed, with multiple large purchases totaling over $90 million. These transactions involved substantial share acquisitions by several entities and an individual, indicating notable insider investment.
Stock chart
Ticker: AKTS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
Foley Todd
1 purchase — total 4,191,660 USD
Buy 12 Jan 2026
Value US$3,851,553.93 | Price 146.96 | Shares 80,757
Buy 12 Jan 2026
Value US$3,783,353.35 | Price 250.36 | Shares 51,569
Buy 12 Jan 2026
Value US$20,029,986.00 | Price 18.00 | Shares 1,112,777
Buy 12 Jan 2026
Value US$2,599,974.00 | Price 18.00 | Shares 144,443
Buy 12 Jan 2026
Value US$37,400,022.00 | Price 18.00 | Shares 2,077,779
Buy 12 Jan 2026
Value US$405,810.00 | Price 18.00 | Shares 22,545
Buy 12 Jan 2026
Value US$14,624,190.00 | Price 18.00 | Shares 812,455
Buy 12 Jan 2026
Value US$405,810.00 | Price 18.00 | Shares 22,545
Buy 12 Jan 2026
Value US$14,624,190.00 | Price 18.00 | Shares 812,455
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-01-14 2026-01-12 B Purchase
2.8
Foley Todd
Non-Executive Director Large shareholder
80,757 -27.4%
146.96
US$3,851,554 		80,757 -27.4% 146.96 US$3,851,554
2026-01-14 2026-01-12 B Purchase
3.1
GADICKE ANSBERT
Large shareholder
51,569 +27.3%
250.36
US$3,783,353 		51,569 +27.3% 250.36 US$3,783,353
2026-01-14 2026-01-12 B Purchase
3.3
MPM BIOVENTURES 2018, L.P.
Large shareholder
84,389 +24.3%
132.85
US$2,979,183 		84,389 +24.3% 132.85 US$2,979,183
2026-01-12 2026-01-12 B Purchase
3.1
EcoR1 Capital, LLC
Non-Executive Director
144,443 +71.2%
18.00
US$2,599,974 		144,443 +71.2% 18.00 US$2,599,974
2026-01-12 2026-01-12 B Purchase
3.1
EcoR1 Capital, LLC
Non-Executive Director
2,077,779 +91.5%
18.00
US$37,400,022 		2,077,779 +91.5% 18.00 US$37,400,022
2026-01-12 2026-01-12 B Purchase
Vida Ventures II, LLC
Large shareholder
22,545 +16.7%
18.00
US$405,810 		22,545 +16.7% 18.00 US$405,810
2026-01-12 2026-01-12 B Purchase
Vida Ventures II, LLC
Large shareholder
812,455 +16.7%
18.00
US$14,624,190 		812,455 +16.7% 18.00 US$14,624,190
2026-01-12 2026-01-12 B Purchase
Kim Helen Susan
Non-Executive Director Large shareholder
22,545 +16.7%
18.00
US$405,810 		22,545 +16.7% 18.00 US$405,810
2026-01-12 2026-01-12 B Purchase
Kim Helen Susan
Non-Executive Director Large shareholder
812,455 +16.7%
18.00
US$14,624,190 		812,455 +16.7% 18.00 US$14,624,190
Explore more

More insider trading research around Aktis Oncology Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America